Insider Transactions in Q2 2021 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
1,067
-0.73%
|
$32,010
$30.04 P/Share
|
|
Jun 09
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
8,933
-5.78%
|
$267,990
$30.05 P/Share
|
|
Jun 02
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
8,200
-19.38%
|
$213,200
$26.69 P/Share
|
|
Jun 01
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
25,800
-26.76%
|
$696,600
$27.01 P/Share
|
|
Jun 01
2021
|
Michael David Smith Senior VP, Development |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$195,000
$26.83 P/Share
|
|
Jun 01
2021
|
Michael David Smith Senior VP, Development |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$60,000
$8.39 P/Share
|
|
May 03
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
6,000
-9.96%
|
$144,000
$24.84 P/Share
|
|
May 03
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+9.06%
|
$60,000
$10.21 P/Share
|
|
May 03
2021
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-10.42%
|
$120,000
$24.84 P/Share
|
|
Apr 29
2021
|
Thomas Andrew Crockett CEO |
SELL
Bona fide gift
|
Direct |
4,750
-2.98%
|
-
|
|
Apr 29
2021
|
Andreas Maetzel Senior Vice President, Medical |
SELL
Open market or private sale
|
Direct |
40,886
-100.0%
|
$1,022,150
$25.04 P/Share
|
|
Apr 29
2021
|
Andreas Maetzel Senior Vice President, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
40,886
+36.47%
|
$408,860
$10.73 P/Share
|
|
Apr 28
2021
|
Michael David Smith Senior VP, Development |
SELL
Open market or private sale
|
Direct |
10,014
-100.0%
|
$250,350
$25.76 P/Share
|
|
Apr 28
2021
|
Michael David Smith Senior VP, Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,014
+50.0%
|
$80,112
$8.39 P/Share
|
|
Apr 28
2021
|
Andreas Maetzel Senior Vice President, Medical |
SELL
Open market or private sale
|
Direct |
36,127
-70.84%
|
$903,175
$25.49 P/Share
|
|
Apr 28
2021
|
Andreas Maetzel Senior Vice President, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
36,127
+50.0%
|
$252,889
$7.91 P/Share
|
|
Apr 27
2021
|
Andreas Maetzel Senior Vice President, Medical |
SELL
Open market or private sale
|
Direct |
11,017
-100.0%
|
$275,425
$25.79 P/Share
|
|
Apr 27
2021
|
Andreas Maetzel Senior Vice President, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
11,017
+50.0%
|
$77,119
$7.91 P/Share
|
|
Apr 01
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.98%
|
$270,000
$27.27 P/Share
|